Novo Nordisk A/S has announced the launch of its acclaimed obesity drug, Wegovy, in China, a strategic move aimed at tapping into the world’s second-largest economy’s burgeoning weight-loss market. The drug, known for its impact on body weight management, will be available at a remarkably lower price compared to its cost in the United States, […]
AI Biotech Generate Secures $65M in Novartis Deal
In a significant move that showcases the growing collaboration between artificial intelligence and biopharmaceuticals, Generate Biomedicines has announced a new partnership with Novartis, a global leader in the pharmaceutical industry. Under this partnership, Novartis is committing an upfront investment of $65 million, comprising $50 million in cash and an additional $15 million in equity. The […]
Ozempic ‘Very Likely’ to Face Drug Price Negotiations, Novo Says
The recent announcement from Novo Nordisk has raised expectations regarding the future pricing of Ozempic, the widely used diabetes medication. At the Cantor Global Healthcare Conference in New York, Ulrich Otte, a senior executive at Novo, stated that Ozempic is “very likely” to be included in upcoming negotiations with the U.S. government around drug prices. […]